WomenCare Global buys two oral contraceptive brands
CHAPEL HILL, N.C. — WomenCare Global has acquired two oral contraceptive brands from ICON, WomenCare said Monday.
The company acquired Roselle (levonorgestrel and ethinylestradiol) and Optinor (levonorgestrel). ICON developed both drugs under a partnership with an unnamed generic drug manufacturer.
“This partnership with WomenCare Global is a significant step forward in expanding access to quality-assured generic hormonal contraceptives at competitive prices,” ICON general manager David Smith said in a statement.
Impax challenges Abbott’s Simcor patent
HAYWARD, Calif. — Generic drug maker Impax Labs is challenging the patent covering a drug used to treat high cholesterol, the company said Friday.
Impax said it had filed an approval application with the Food and Drug Administration for niacin and simvastatin extended-release tablets in the 1,000 mg/20 mg strength. The drug is a generic version of Abbott Labs’ Simcor.
Impax’s application contained a paragraph IV certification, a legal assertion under the Hatch-Waxman Act of 1984 that the patent covering Simcor is invalid or unenforceable, or that Impax’s version won’t infringe upon it. Abbott responded last Wednesday by filing a patent infringement suit against Impax in the U.S. District Court for the District of Delaware.
APhA Foundation taps exec search firm to find replacement for Ellis
WASHINGTON — Moving a step closer to filling a leadership void, the American Pharmacists Association Foundation said Monday it has tapped The Bernard Consulting Group, an executive search firm, to assist with the search for the next executive director and CEO of the organization.
The nationwide search for a new top executive will begin in January, with a decision on a new CEO expected from the APhA Foundation’s board by next July. Meanwhile, the group will be led by interim executive director Elizabeth Keyes. Keyes, who is chief business officer and SVP-business strategy and operations for the American Pharmacists Association, was tapped to fill temporarily the management void left by the departure in September of William Ellis, who left to become executive director of the Board of Specialty Pharmacies after serving as APhA Foundation’s CEO for 13 years.
The foundation is a nonprofit affiliate that works to design solutions to medication use problems in the U.S. Among its most notable successes over the past decade has been the launch of Project ImPACT programs to demonstrate the value of pharmacist-delivered screenings and disease management programs for hyperlipidemia and osteoporosis, as well as the Patient Self-Management Program for Diabetes.
“The foundation will continue to focus its work on promoting advancements in pharmacy practice and using practice-based research to develop collaborative practice models for programs that truly help patients achieve better outcomes in their health care,” said Keyes. “I am excited to work with the foundation staff and board of directors to assist in their search for and transition to new executive leadership.”